Background: There is limited long-term follow-up of patients undergoing parathyroidectomy. Recurrence is described as 4% to 10%. This study evaluated persistence and recurrence of hypercalcemia in primary hyperparathyroidism after parathyroidectomy. Methods: Single-institution retrospective (1965–2010) population-based cohort from Olmsted County (MN) of patients undergoing surgery for primary hyperparathyroidism. Patients’ demographic data, preoperative and postoperative laboratory values, clinical characteristics, surgical treatment, and follow-up were noted. Results: A total of 345 patients were identified, 75.7% female, and median age 58.4 years [interquartile range (IQR): 17.6]. In all, 68% of patients were asymptomatic and the most common symptoms were musculoskeletal complaints (28.4%) and nephrolithiasis (25.6%). Preoperative median serum calcium was 11 mg/dL (IQR: 10.8–11.4 mg/dL), and median parathyroid hormone was 90 pg/mL (IQR: 61–169 pg/dL). Bilateral cervical exploration was performed in 38% and single gland resection in 79% of cases. Median postoperative serum calcium was 9.2 mg/dL (IQR: 5.5–11.3). Nine percent of patients presented persistence of hypercalcemia, and recurrence was found in 14% of patients. Highest postoperative median serum calcium was 10 mg/dL (IQR: 6–12.4), and median number of postoperative calcium measurements was 10 (IQR: 0–102). Postoperative hypercalcemia was identified in 37% of patient. Fifty-three percent were attributed to secondary causes, most commonly medications, 22%. Three percent of patients required treatment for postoperative hypercalcemia. Median time to recurrence and death were 12.2 and 16.7 years, respectively. Conclusion: Recurrent hypercalcemia after successful parathyroidectomy is higher than previously reported. Most cases are transient and often associated to other factors with only the minority requiring treatment. Long-term follow-up of serum calcium should be considered in patients after successful parathyroidectomy.
Donation after circulatory death (DCD) has expanded the donor pool for liver transplantation. However, ischemic cholangiopathy (IC) after DCD liver transplantation causes inferior outcomes. The molecular mechanisms of IC are currently unknown but may depend on ischemia-induced genetic reprograming of the biliary epithelium to mesenchymal-like cells. The main objective of this study was to determine if cholangiocytes undergo epithelial to mesenchymal transition (EMT) after exposure to DCD conditions and if this causally contributes to the phenotype of IC. Human cholangiocyte cultures were exposed to periods of warm and cold ischemia to mimic DCD liver donation. EMT was tested by assays of cell migration, cell morphology, and differential gene expression. Transplantation of syngeneic rat livers recovered under DCD conditions were evaluated for EMT changes by immunohistochemistry. Human cholangiocytes exposed to DCD conditions displayed migratory behavior and gene expression patterns consistent with EMT. E-cadherin and CK-7 expressions fell while N-cadherin, vimentin, TGFβ, and SNAIL rose, starting 24 hours and peaking 1–3 weeks after exposure. Cholangiocyte morphology changed from cuboidal (epithelial) before to spindle shaped (mesenchymal) a week after ischemia. These changes were blocked by pretreating cells with the Transforming Growth Factor beta (TGFβ) receptor antagonist Galunisertib (1 μM). Finally, rats with liver isografts cold stored for 20 hours in UW solution and exposed to warm ischemia (30 minutes) at recovery had elevated plasma bilirubin 1 week after transplantation and the liver tissue showed immunohistochemical evidence of early cholangiocyte EMT. Our findings show EMT occurs after exposure of human cholangiocytes to DCD conditions, which may be initiated by upstream signaling from autocrine derived TGFβ to cause mesenchymal specific morphological and migratory changes.
Introduction: Mitochondrial dysfunction from global ischemic-reperfusion (I/R) injury is a major contributor to post-resuscitation myocardial dysfunction. Polyethylene Glycol-20k (PEG-20k) shortens the no-flow phenomenon and improves microcirculation while MCC950 selectively inhibits activation of the NLRP3-inflammasome ensuing pyroptosis. We evaluated the effect of combined therapy with PEG-20k and MCC950 on myocardial mitochondrial function as measured by electron transport chain complex respiration in a rat model of cardiac arrest (CA) and cardiopulmonary resuscitation (CPR). Methods: 30 Sprague-Dawley rats weighing between 450-550 g were randomized into five groups (n=6): (1) sham (S); (2) control (C); (3) PEG-20k (P); (4) MCC950 (M); (5) combined (P&M). Ventricular fibrillation (VF) was electrically induced and untreated for 6min, followed by 8min CPR. Resuscitation was attempted with a 4J defibrillation. 2mL P was infused over 2 min at the beginning of CPR, while M (10mg/kg) was administered intraperitoneal (IP) immediately after return of spontaneous circulation (ROSC). At ROSC 6hr, 100mg of heart was harvested, transferred directly into ice-cold K medium (1mL), and homogenized to obtain a 10% homogenate. Homogenates (50μL) were transferred to calibrated Oxygraph-2 chambers. Mitochondrial function was measured using high resolution respirometry. Oxygen flux was corrected and expressed by tissue wet weight, pmol/(min*mg). Data were analyzed by one-way analysis of variance (one-way ANOVA) followed by Tukey’s post hoc test for comparisons between multiple groups. Results: Complex I respiration in C was compromised at ROSC 6hr compared to S (564.0±160.0 vs 2729.5±339.5, p<0.001). As expected, P and M restored complex I respiration (1224.4±328.6, p<0.001) and (1804.4±293.1, p<0.01) compared to C. P&M further consolidated Complex I respiration function recovery (2527.6±145.5). Conclusion: Combined Therapy with PEG-20k and MCC950 preserves post-resuscitation myocardial mitochondrial function in a rat model of CA and CPR.
Cholestatic liver diseases, such as primary sclerosing cholangitis and primary biliary cirrhosis, can lead to serum accumulation of lipoprotein X (LpX). LpX is a multilamellar particle high in cholesterol but lacking structural apolipoproteins A1 or B. The absence of ApoB results in no negative feedback on cholesterol biosynthesis and prevents LpX clearance from the liver. While clinical signs and symptoms typically precede laboratory findings, it is possible that in medically complex patients the identification of LpX could be the first observation of cholestatic liver disease. Traditional laboratory methods are insufficient to identify LpX as it is of similar density to low-density lipoprotein (LDL). LpX contains a high concentration of cholesterol which is erroneously reported as LDL-C by routine clinical methods. As LpX is a rare complication of liver disease, clinicians may presume the elevation is a coincidental familial hypercholesterolemia rather than a sequela of liver disease. Currently, lipoprotein gel electrophoresis is the only laboratory method to identify LpX. In this method only performed in specialty lipid laboratories, LpX is readily identified by its unique reverse electrophoretic mobility relative to other lipoproteins. The objective of this study was to characterize lipid panels from LpX-positive samples and develop a suitable mechanism to identify LpX-containing samples with good clinical validity. From 21,377 clinical electrophoresis results reported between Nov 2011 to Nov 2021, LpX was identified in 157 serum samples. Overall, patients with LpX were younger (median 44y vs. 55y, p<0.0001) with significantly higher total cholesterol (812mg/dL vs 190mg/dL, p<0.0001) and lower high density lipoprotein-cholesterol (HDL-C; 3mg/dL vs 45mg/dL, p<0.0001). Data were randomly split (70/30) into training (n=14,964) and testing (n=6,413) cohorts. Receiver operator characteristic curve analysis identified optimal thresholds of 22.5 mg/dL HDL-C (AUC = 0.94) and 378.5 mg/dL total cholesterol (AUC = 0.91), as well as a nonHDL-C/HDL-C ratio of 9.2 (AUC = 0.995). Applying these cutoffs to the testing cohort achieved a sensitivity/specificity of 98%/81% for HDL-C, 96%/87% for total cholesterol, and 98%/94% for nonHDL-C/HDL-C ratio. A multivariate model combining these three parameters showed a sensitivity/specificity of 97%/85%, respectively. In conclusion, low HDL-C, elevated total cholesterol and a ratio of nonHDL-C/HDL-C >9.2 are associated with the presence of LpX. The ratio of nonHDL-C/HDL-C is the most sensitive and specific predictor of LpX. If confirmed in other cohorts, laboratories could include a reporting comment on lipid panels with a nonHDL-C/HDL-C ratio >9.2 cautioning a high suspicion for the presence of LpX and recommending confirmatory testing. It may also be prudent to caution that LDL-C results may not be accurate. In conclusion, identifying patients with high suspicion of LpX based on abnormal lipid panel results may aide in clinical diagnosis, even when an assay to detect LpX is not readily available.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.